CHO cell lines usually adopt the Fed-Batch approach as a primary method to manufacture therapeutic recombinant protein products. Process development for this method has been usually on how best to support high-cell density cultures that are necessary to achieve high product titres production.
The issue however has always been the high nutritional demands required. If there is a lack of key nutrients, cell growth will be affected and with it, the inability to produce these proteins.
Bayer Healthcare partnered with Life Technologies (now Thermo Fisher Scientific) and implemented a novel, propriety nutrient addictive GIBCO FunctionMAX Titer Enhancer, and combined it with several other feeds to enhance CHO Cell Culture performance.
What are your usual approaches to Fed-Batch Cell Culture Process Development? Share it with us and let’s look at what could be the others that Upstream Process development teams worldwide can adopt!
Cell Culture is a key component at the BioPharma Asia Convention 2015. With Asia’s biopharma moving even faster into manufacturing, delegates are now becoming more curious on adopted approaches and weighing the possibilities of using them for themselves.
Check out the BioPharma Asia Convention 2015 over here.